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Objectives: Successful surgical management of thoracic aortic aneurysms (TAA) and thoracoabdominal aortic aneurysms
(TAAA) has historically relied upon open surgical repair (OSR). More recently, the advent and application of thoracic
endovascular stent graft aneurysm repair (TEVAR) permutations have become increasingly performed in contemporary
practice. To better determine the effect of TEVAR techniques on OSR, we examined national and regional trends in
treatment use.
Methods: All Medicare patients from 1998 through 2007 undergoing isolated TAA and TAAA repair were analyzed using
a clinically validated algorithm using diagnostic International Classification of Disease 9th revision (ICD-9; 441.1,
441.2, 441.6, 441.7, 441.9) codes and procedural (ICD-9 OSR: 38.35, 38.45 and TEVAR: 39.73, 39.79) codes.
Differential rates of OSR and TEVAR were compared across census tract regions during the study interval.
Results: Total complex aortic repairs increased by 60%, from 10.8 to 17.8/100,000, between 1998 and 2007 (P< .001).
A dramatic increase occurred in TEVAR (not performed in 1998, 5.8/100,000 in 2007) during the study period, but
OSR rates remained stable during the same interval (10.7 to 12.0/100,000 in 2007, P  NS). There was substantial
regional variation for both OSR and TEVAR. This regional variation was greater in OSR (range, 8.8-16.7/100,000)
than in TEVAR (range, 4.5-6.9/100,000).
Conclusions: Degenerative TAA and TAAA aneurysms are being repaired in the United States at an increasing rate. This
reflects the rapid acceptance of TEVAR, which apparently supplements rather than supplants OSR. There appears to be
greater regional variation in OSR compared with TEVAR. These data may have significant implications for those
interested in the effect of new technologies on health care and cost containment. (J Vasc Surg 2011;53:1499-505.)
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tOpen surgical repair (OSR) has been the main stay of
therapy for the treatment of degenerative aneurysmal dis-
ease in the thoracic aorta (TAA) and thoracoabdominal
aorta (TAAA) for nearly 4 decades.1-3 An increase in the
incidence of thoracic aortic pathology has been docu-
mented during this interval, likely related to the widespread
application of improved diagnostic modalities.4,5 This has
resulted in an increased demand for thoracic aortic inter-
vention. However, despite the advent of high-volume cen-
ters of excellence, operative mortality and associated mor-
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doi:10.1016/j.jvs.2011.02.014idities remain in the 10% range.1,4-6 The adoption of
horacic endovascular aortic aneurysm repair (TEVAR) has
een reported to decrease morbidity, paraplegia risk, and
hort-term mortality rates. Such favorable outcomes have
esulted in the rapid and widespread application of TEVAR
n contemporary practice.7-10
Associated costs referable to OSR of TAAA have been
reviously estimated to be as high as $119,000.11 Earlier
eries have documented net hospital losses, particularly in
AAA patients undergoing OSR, primarily due to in-
reased lengths of stay.12 The initial cost-analysis data for
he use of TEVAR demonstrate that either equivalent or
nly slightly reduced (range, $10,000-$20,000) associated
osts to the patient and the insurers can be anticipated.13,14
his partly reflects the high associated costs for currently
vailable commercial devices.
The rapid adoption of endovascular therapies in other
natomic locations for a variety of vascular disease pro-
esses, including lower extremity revascularization, has had
significant effect on decreasing the rate of OSR.15 The
ntroduction of endoluminal therapies in the mesenteric
irculation for acute mesenteric ischemia was heralded with
n initial decrease in OSR over time.16 In a similar fashion,
he effect of EVAR for infrarenal AAA disease has been
ccompanied by a significant decrease in the number of
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June 20111500 Scali et alpatients undergoing OSR.17 The purpose of this study was
to determine the effect of TEVAR on rates of OSR to
document current national trends in treatment use.
METHODS
Database. The Medicare Provider Analysis and Re-
view (MEDPAR) file was interrogated. Part A claims data
analysis was performed on all Medicare beneficiaries under-
going open and endovascular treatment of TAA and TAAA
from 1998 through 2007. The data in this file include
demographic information, admission-related diagnostic In-
ternational Classification of Diseases, 9th Revision (ICD-9)
codes, operative Current Procedural Terminology (CPT)
codes (American Medical Association, Chicago, Ill), dis-
charge data, and hospital charges on Medicare admissions
to certified hospitals and skilled nursing facilities. Proce-
dures were identified by using a combination of CPT codes,
diagnostic, and procedural ICD-9 codes using a clinically
validated algorithm. The clinical algorithm consisted of a
record review of a random sample of 20 records from two
institutions of preidentified patients with a known history
of TAA or TAAA repair.
Coding strategy. The coding strategy included cap-
ture of all ruptured and nonruptured TAA and TAAA open
(ICD-9: 38.35, 38.45; CPT: 33875, 33877, 35091,
35092) and endovascular repairs (ICD-9: 39.79; CPT:
33880, 33881, 33883, 33884, 33886). In addition, open
and endovascular repair of thoracic and thoracoabdominal
dissection were analyzed if a code for aneurysm was also
found because many of these are likely for chronic dissec-
tion with aneurysmal degeneration (ICD-9: 441, 441.1,
441.2, 441.7, 441.03).
Excluded were patients with concomitant codes for
valve replacement, coronary artery bypass, grafting cardio-
plegia, aorta-to-great vessel bypass, and hypothermic ar-
rest. An inclusionary code (ICD-9 441.9) for all aortic
aneurysms of unspecified site, without mention of rupture,
aneurysm, dilatation of the aorta, or hyaline necrosis of the
Fig 1. International Classification of Diseases, 9th edition and
Current Procedural Terminology coding strategy for thoracic aor-
tic aneurysms (TAA) and thoracoabdominal aortic aneurysms
(TAAA) TEVAR, Thoracic endovascular aortic aneurysm repair.aorta, was also arrogated (Fig 1). This strategy was used in wn attempt to eliminate patients with ascending aortic
neurysms and type A dissection while maximizing capture
f the TAA and TAAA repairs. This algorithm was piloted
t Dartmouth-Hitchcock Medical Center and the Univer-
ity of Florida and was accurate in identifying hospital
dmissions for thoracic endovascular and open procedures.
Geographic analysis. After the inclusion criteria were
stablished, information derived from the Medicare De-
ominator file was analyzed to ascertain the geographic
ariation in incidence of each procedure over time between
998 and 2007. Data were analyzed between nine census
ract regions of the United States, as defined by the U.S.
ensus Bureau (Fig 2). Census tract regions are census
reas or districts that often coincide with the limits of cities,
owns, or other administrative areas, and several tracts
ommonly exist within a county. Census tracts represent
he smallest territorial units for which population data are
vailable in many countries, including the United States
http://www.census.gov).
Statistics. We used t tests to compare rates between
egions. Nonparametric tests of trend were used to test
ignificance across years; values of P .05 were considered
ignificant. All analyses were performed using SAS (SAS
nstitute, Cary, NC), and STATA 10 software (StataCorp,
ollege Station, Tex).
ESULTS
Changes in use of OSR and TEVAR. During the
tudy interval from 1998 to 2007, the total repair rate of
AA and TAAAs increased substantially. In 1998, 10.8
rocedures were performed per 100,000 Medicare benefi-
iaries (Fig 3). By 2007, however, this rate increased by
0% to 17.8/100,000 (P  .001). This increase in the
epair rate was due almost entirely to a rapid increase in
he use of TEVAR. OSR procedures for thoracic and
AAA modestly increased by 10.8%, from 10.7/
00,000 beneficiaries in 1998 to 12/100,000 beneficia-
ies in 2007 (P  NS).
In contrast, a dramatic increase was demonstrated in
he use of endovascular repair, which was not performed in
998. As shown in Fig 3, a more rapid application of
ndovascular repair of TAA and TAAA appears to have
ccurred after 2004. This likely coincides with the publica-
ion of the GORE TAG trial results and availability of the
EVAR CPT code in 2005. During a 3-year interval from
004 to 2007, the proliferation of TEVAR in contempo-
ary practice resulted in a greater than threefold increase in
se across the United States. By 2007, the national rate of
EVAR use for isolated thoracic and TAAA repairs had
ncreased to 5.8 procedures per 100,000.
In 2000, only 1.6% of all thoracic procedures in the
tudy cohort were performed using TEVAR, and 98% were
erformed with OSR. Among OSRs, nearly 40% were
erformed for descending TAA (DTAA), 21% for TAAA,
nd 29% for aortic dissection–related etiologies. Ruptured
neurysms constituted 6% of the descending TAA cohort
nd 4% of the TAAA group. In contrast, by 2007, repairs
ere endovascular in 31% of the study group and open in
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Volume 53, Number 6 Scali et al 150169%. Among patients undergoing TEVAR repair, 51% had
descending TAA, 22% had TAAA, 17% were performed for
aortic dissection–related pathology, such as aneurysmal
degeneration, 7% were performed for ruptured DTAA, and
2% were performed for ruptured TAAA. Among those
patients undergoing open repair, 54% were performed for
DTAA, 12% for TAAA, 28% for aortic dissection-related
pathology, 3% for ruptured DTAA, and 2% for ruptured
TAAA. Because of coding imprecision, these groups were
collectively aggregated to better reflect treatment use over
time (Table).
Regional variation. To better understand the most
recent effect and use of OSR and TEVAR on regional
variation, a geographic analysis of the adaptation of the two
therapies across nine census tract regions was compared
within the year 2007 (Fig 4). Relatively comparable rates of
TEVAR use across census tract regions were seen, with a
range of 4.5 to 6.9/100,000 Medicare beneficiaries. The
extent of variation in repair rates across regions was greater
for OSR (range 8.8-16.7/100,000) than TEVAR (range
Fig 2. Map shows the nine census tract regions of th
Adapted from http://www.census.gov/factsheet.4.5-6.9/100,000) in both absolute and relative terms. sISCUSSION
This study provides a view of the current trends in
reatment of TAA and TAAA in Medicare patients. These
ndings confirm TEVAR has increased significantly on a
ational level.8,18-20Unlike other vascular disease processes
n the extracranial carotid, mesenteric, or infrarenal aortic
erritories, endovascular treatment of degenerative aneu-
ysms in the thoracic and thoracoabdominal aorta appears
o have increased the total number of repairs.18-20 This
apid increase is largely due to TEVAR, whereas rates of
SR have remained relatively stable. In addition, TEVAR
ates vary much less across regions than OSR. This suggests
hat the relative technical simplicity and reduction in resource
tilization of TEVAR compared with OSR have promoted
apid and more uniform adoption across the country.
Previously, the advent of new endoluminal therapies
as been associated with its rapid substitution for its open
urgical counterpart, as seen in the cerebrovascular circula-
ion with carotid endarterectomy (CEA) and carotid artery
ited States, as designated by the U.S. Census Bureau.e Untenting (CAS). The dissemination of CAS into 95% of
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June 20111502 Scali et alhospital referral regions has occurred with apparent substi-
tution of CEA, explaining an overall decline in open surgi-
cal reconstruction in the extracranial carotid circulation.
This change in carotid revascularization patterns occurred
before the comparative effectiveness of the two therapies
was adequately analyzed in the surgical literature.21
This precedent is again seen in other index vascular
procedures, such as treatment of mesenteric arterial occlu-
sive disease. Schermerhorn et al16 described an overall
decrease in the number of open surgical procedures for the
treatment of acute mesenteric ischemia alone, while a rapid
increase in angioplasty, with or without stenting, was ob-
served. In a similar fashion, endovascular management of
Fig 3. Rates of total thoracic and thoracoabdominal a
endovascular repair (triangles) in Medicare patients, 199
Table. Aggregated pathology and method of repair for
thoracic aortic and thoracoabdominal aortic aneurysms
among Medicare beneficiaries from 2000 to 2007
Variable
Total cohort
(%)
OSR
(%)
TEVAR
(%)
Nonruptured
Descending thoracic
aneurysms 49 83 17
Thoracoabdominal aneurysms 17 81 19
Dissection 26 90 10
Other (thoracic aortic
pathology) 0.3 55 45
Ruptured
Descending thoracic
aneurysms 5 77 23
Thoracoabdominal aneurysms 3 89 11
OSR,Open surgical repair; TEVAR, thoracic endovascular aneurysm repair.aneurysm disease localized to the infrarenal aorta has been nssociated with substantial change in treatment paradigms.
VAR has decreased rates of OSR while leading to in-
reased variability of procedure rates across the United
tates. This may be consistent with the hypothesis that
roadening the indications—perhaps to patients at higher
isk for OSR—has led to greater variability in clinical deci-
ion making.17
Perhaps the most dramatic effect of catheter-based
herapies on the management of vascular disease is demon-
trated in infrainguinal arterial reconstruction. Between
996 and 2006, the national rate of lower extremity periph-
ral interventions increased nearly threefold, whereas open
urgical bypass decreased by 42%.15
The reason why endoluminal therapy for TAA and
AAA appears to supplement rather than supplant open
epair may be due to a number of factors. Traditional open
epair of these types of aneurysms requires formidable skill
nd enormous clinical resources driving a concentration on
enters of excellence as a cardinal concept in the field.3
urrent OSR of DTAA and TAAA can anticipate good
hort-term and long-term technical and functional out-
omes.3,22 Although recent reports have begun to espouse
imilar notions in the endovascular management of acute
ortic syndromes, this perception is not fully proven.4,5
his is likely reflected in the relatively consistent use of
EVAR across census tract regions compared with the
ignificant variability with OSR (Fig 4). Within 3 years of
.S. Food and Drug Administration (FDA) approval,
EVAR rates across a variety of geographic regions had effec-
ively tripled and have very little variance in utilization. This
ppears to support the notion ofwidespread acceptance of this
aneurysm repair (diamonds), open repair (squares) and
07. CI, Confidence interval.orticew technology in modern vascular surgery practice.
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Volume 53, Number 6 Scali et al 1503Another potential explanation for the additive nature of
endovascular treatment in the thoracic and thoracoab-
dominal aorta to overall utilization rates is that a variety of
authors have demonstrated good short-term and midterm
results with TEVAR and an attendant low morbidity and
mortality rate. These early experiences may have incited
enthusiasm amongst a number of providers across different
disciplines, leading to the rapid development of TEVAR
programs in hospital systems that may not routinely per-
form open TAA or TAAA repair. In addition, it is quite
possible that treatment thresholds or operative risk profiles
are different between patients treated with TEVAR vs OSR
because these trends were initially seen with the introduc-
tion of EVAR in the management of aneurysms isolated to
the infrarenal aorta.23,24
An interesting question is specifically which types of
aneurysms are being treated with TEVAR? Unlike a num-
ber of aortic pathologies, such as dissection, penetrating
aortic ulcer, or traumatic disruption, TAAAs have the
added complexity and routine prerequisite of branch vessel
preservation as part of the definitive repair strategy. Cur-
rently available devices in the United States do not readily
accommodate this requirement unless branched, fenes-
trated, or chimney techniques are used.25 Given the added
complexity of treating visceral-segment aneurysm disease,
one could hypothesize that national rates for OSR for such
lesions would remain stable. In addition, this may explain the
greater regional variationwithOSRbecause volume-outcome
relationships and tertiary medical centers with designated in-
terest for TAAA will affect referral patterns.
This finding of stable rates for OSR for aneurysmal
disease in the DTAA and the TAAA brings into sharp
relief the current management of isolated, degenerative
Fig 4. Regional variation in use of open and endova
(TEVAR) among Medicare beneficiaries in 2007.DTAA. Several clinical trials have documented clinical dquipoise between open repair and endovascular repair
f DTAA.8,9,26-28 These data, combined with the demon-
tration of lower short-term morbidity, have resulted in a
aradigm shift in the management of these lesions29 that
as occurred despite a lack of level 1 evidence to support
he widespread use of this technology.Moreover, a consen-
us statement by the Society of Thoracic Surgeons Endo-
ascular Surgery Task Force recently described the lack of
rospective, randomized data comparing the two types of
epairs in the same aortic pathology.30
Another point sustaining debate about the appropriate
pplication of these two treatments is that many patients
ho undergo TEVAR for isolated TAA require lifelong
urveillance and often require reintervention, leading to
igher downstream costs compared with OSR.31 Issues of
raft migration, collapse, and endoleak are not infrequent
omplications of endovascular therapies in this region of
he aorta.32,33 Despite newly found enthusiasm for the
doption of endovascular techniques for the management
f disease traditionally repaired by OSR, lessons can be
earned from the potentially negative implications of re-
ional variation in the application of other index vascular
rocedures, such as stroke risk and CEA.34
This study has several limitations, including the poten-
ial coding errors that are encountered with an administra-
ive database. The procedural ICD-9 and CPT codes spe-
ific for TEVAR (39.79; 33880, 33881, 33883, 33884,
3886) were not routinely used throughout the study
nterval by Centers for Medicare and Medicaid Services.
dditionally, endovascular therapies are often used off-
abel, and some patients may have undergone intervention
or nonaneurysmal disease. It is unclear if these misclassifi-
ations did occur or whether it would be systematically
r repair of thoracic and thoracoabdominal aneurysmssculaifferent year to year. This may possibly have introduced
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not analyzed in this study, so definitive conclusions cannot
be drawn about how open and endovascular repair com-
pare.
Another limitation of this analysis is that there are no
current FDA-approved therapies for TAAAs in the United
States, so drawing definitive conclusions about the effect
TEVAR has on these aneurysms is not possible at this time.
Although one can speculate that TEVAR is strictly affecting
the management of isolated DTAAs nationally, the full
effect of coding errors, debranching, chimney techniques,
and homemade fenestrated endografting is not known.
To gain a complete perspective on the current national
management of all TAA and TAAA during the initial phases
of TEVAR utilization, these pathologies were queried to-
gether. It is likely that the boundaries between isolated
DTAAs and TAAA will become increasingly blurred as
newer endovascular technologies are developed. These data
will provide a reference point against which future studies
can be compared once fenestrated branched technology
begins to permeate into the U.S. treatment paradigm of
degenerative aneurysmal disease of the thoracic and thora-
coabdominal aorta.
Lastly, this study demonstrates differences in use of
OSR and TEVAR for TAA and TAAA, but whether this
variation represents overuse or underuse of the two thera-
pies across regions remains uncertain. To answer this ques-
tion, a study of indications and a comparison of outcomes
data are needed to fully understand the clinical effect of
TEVAR vs OSR in the treatment of TAA and TAAA
disease. Unfortunately, the relatively widespread and uniform
acceptance ofTEVARnationallywould likelymake a random-
ized, prospective trial virtually impossible to perform. Some
practitioners may even believe such a trial would be unethical
in light of the contemporary data supporting the superiority of
TEVAR to OSR with regard to short-term morbidity and,
possibly, in-hospital mortality.24,31
CONCLUSIONS
Repair rates in the United States for degenerative TAA
and TAAA increased from 1998 to 2007. Unlike in alter-
nate anatomic locations, endovascular management of tho-
racic aortic pathology has not supplanted but has supple-
mented historical treatment paradigms. These data may
have significant implications for the application of new
technologies and health care cost containment. Because
national practice patterns can change rapidly in response to
innovation, rapidly performed, accurate analyses compar-
ing clinical efficacy and cost-effectiveness are needed to
keep these changes rational.
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